23ANDME HOLDING CO -CLASS A (ME) Stock Price, Quote, News and Overview
NASDAQ:ME - Nasdaq - US90138Q3065 - Common Stock - Currency: USD
ME Quote, Performance and Key Statistics
0.6063
-0.16 (-21.26%)
The current stock price of ME is 0.6063 USD. In the past month the price decreased by -72.44%. In the past year, price decreased by -94.3%.
ME Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 12.07 | 89.50B | ||
| CVS | CVS HEALTH CORP | 12.42 | 84.95B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.16 | 18.28B | ||
| LH | LABCORP HOLDINGS INC | 14.9 | 18.17B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 12.78 | 13.88B | ||
| DVA | DAVITA INC | 14.74 | 11.20B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 110.15 | 10.60B | ||
| CHE | CHEMED CORP | 25.14 | 8.50B | ||
| HIMS | HIMS & HERS HEALTH INC | 50.43 | 6.05B | ||
| CRVL | CORVEL CORP | 27.53 | 5.91B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.55B | ||
| OPCH | OPTION CARE HEALTH INC | 26.25 | 5.26B |
Related stock screener links
About ME
Company Profile
23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California and currently employs 560 full-time employees. The company went IPO on 2020-10-06. The firm operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Company Info
23ANDME HOLDING CO -CLASS A
349 Oyster Point Boulevard
South San Francisco CALIFORNIA US
CEO: Josh Bayliss
Employees: 560
Company Website: https://investors.23andme.com/
Investor Relations: https://investors.23andme.com/
Phone: 16509386300
23ANDME HOLDING CO -CLASS A / ME FAQ
What is the stock price of 23ANDME HOLDING CO -CLASS A today?
The current stock price of ME is 0.6063 USD. The price decreased by -21.26% in the last trading session.
What is the ticker symbol for 23ANDME HOLDING CO -CLASS A stock?
The exchange symbol of 23ANDME HOLDING CO -CLASS A is ME and it is listed on the Nasdaq exchange.
On which exchange is ME stock listed?
ME stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 23ANDME HOLDING CO -CLASS A stock?
9 analysts have analysed ME and the average price target is 2.12 USD. This implies a price increase of 249.93% is expected in the next year compared to the current price of 0.6063. Check the 23ANDME HOLDING CO -CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 23ANDME HOLDING CO -CLASS A worth?
23ANDME HOLDING CO -CLASS A (ME) has a market capitalization of 16.27M USD. This makes ME a Nano Cap stock.
How many employees does 23ANDME HOLDING CO -CLASS A have?
23ANDME HOLDING CO -CLASS A (ME) currently has 560 employees.
Is 23ANDME HOLDING CO -CLASS A (ME) expected to grow?
The Revenue of 23ANDME HOLDING CO -CLASS A (ME) is expected to grow by 22.44% in the next year. Check the estimates tab for more information on the ME EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy 23ANDME HOLDING CO -CLASS A (ME) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ME, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ME, evaluating the profitability, health, valuation and growth aspects
- 23ANDME HOLDING CO -CLASS A (ME) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 23ANDME HOLDING CO -CLASS A (ME) Sales and EPS estimates to see what analysts future expectations are.
- 23ANDME HOLDING CO -CLASS A (ME) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 23ANDME HOLDING CO -CLASS A (ME) Insider and Institutional Ownership to learn about the owners and their transactions.
- 23ANDME HOLDING CO -CLASS A (ME) Stock Chart to make your own analysis
- 23ANDME HOLDING CO -CLASS A (ME) Latest news and press-releases to stay up to date.
Does 23ANDME HOLDING CO -CLASS A (ME) stock pay dividends?
ME does not pay a dividend.
What is the Price/Earnings (PE) ratio of 23ANDME HOLDING CO -CLASS A (ME)?
23ANDME HOLDING CO -CLASS A (ME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.2).
What is the Short Interest ratio of 23ANDME HOLDING CO -CLASS A (ME) stock?
The outstanding short interest for 23ANDME HOLDING CO -CLASS A (ME) is 9.8% of its float. Check the ownership tab for more information on the ME short interest.
ME Technical Analysis
ME Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ME. While ME seems to be doing ok healthwise, there are quite some concerns on its profitability.
ME Financial Highlights
Over the last trailing twelve months ME reported a non-GAAP Earnings per Share(EPS) of -13.2. The EPS decreased by -29.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -138.01% | ||
| ROE | -545.25% | ||
| Debt/Equity | 0 |
ME Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 38% to ME. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -329.17% and a revenue growth 22.44% for ME